Growing Need for Companion Diagnostics is Evident at Drug Discovery Event
The momentum for targeted therapies has downstream implications for clinical laboratories
Already a member? Log in here
Author Information
Scott Wallask
Scott Wallask is senior editorial manager at G2 Intelligence and its sibling brands, The Dark Report and Today’s Clinical Lab. During his 30-year career, he has covered the clinical lab, healthcare, and high-tech markets during stints at TechTarget, HCPro, ZoomInfo, and the SAPinsider family of online publications. A former newspaper reporter, he graduated from Northeastern University with a bachelor’s degree in journalism. He can be reached at swallask@clinicallab.com.
Posts by the Author
What the $1b Roche-PathAI Deal Can Tell Clinical Lab Directors
Roche acquires a workflow rather than a company, says AI industry observer
Already a member? Log in here
CLIA-lcaCLIA-nirCMS-lcaCMS-lirCMS-nirEssentialFDA-lcaFDA-lirFDA-nirLab Industry AdvisorLegislation-lcaLegislation-lirLegislation-nirScott Wallask
New Enhancing CLIA Act: What Lab Directors Need to Know
The proposal seeks to move any future LDT authority away from the FDA
Already a member? Log in here
CLIA-lcaCLIA-nirCMS-lcaCMS-lirCMS-nirCompliance-lcaCompliance-nirEssentialLab Industry AdvisorScott Wallask
How to Stay Ahead of Anticipated CLIA Deficiencies
Consultant Nora Hess offers suggestions for clinical labs to navigate these problems
Already a member? Log in here
CLIA-lcaCLIA-nirCMS-lcaCMS-lirCMS-nirEnforcement-lcaEnforcement-lirEnforcement-nirEssentialHealth care reform-lirLab Industry AdvisorLegislation-lcaLegislation-lirLegislation-nirPAMA-lirReimbursement-lcaReimbursement-lirReimbursement-nirScott Wallask
Four Federal Efforts to Monitor, Including RESULTS Act Progress
Other proposals aim to increase fraud enforcement, temper prior authorization, and modernize CLIA
Already a member? Log in here
Coding-lcaCompliance-lcaCompliance-nirEssentialLab Industry AdvisorOIG-nirReimbursement-lcaReimbursement-lirReimbursement-nirScott Wallask
OIG Report on Lab Testing Should Prompt Compliance Review
Genetic testing now accounts for 43 percent of all Medicare Part B laboratory spending
Already a member? Log in here
CMS-lcaCMS-lirCMS-nirEssentialFee Schedules-lirFee Schedules-nirLab Industry AdvisorReimbursement-lcaReimbursement-lirReimbursement-nirScott Wallask
Up Next for Labs: PAMA Reporting Window Opens May 1
Cuts to reimbursement rates under PAMA have been pushed back again by Congress, this time to January 2027
Already a member? Log in here
EssentialFee Schedules-lirFee Schedules-nirLab Industry AdvisorLegislation-lcaLegislation-lirLegislation-nirPAMA-lirReimbursement-lcaReimbursement-lirReimbursement-nirScott Wallask
PAMA Delay Proposed Until 2027 Under a New Federal Spending Bill
However, attorney Danielle Sloane urges labs to be proactive about potential PAMA reporting requirements on Jan. 31 if the bill doesn’t pass quickly
Already a member? Log in here
EssentialFee Schedules-lirFee Schedules-nirLab Industry AdvisorLegislation-lcaLegislation-lirLegislation-nirPAMA-lirReimbursement-lcaReimbursement-lirReimbursement-nirScott Wallask
ACLA Head Pushes RESULTS Act Passage During House Subcommittee Testimony
Better clinical laboratory test data reporting would allow ‘Medicare rates to be more appropriately set,’ says Susan Van Meter
Already a member? Log in here
Genetic Testing Kickback Scheme Results in 46-Month Prison Term
Federal prosecutors continue to target situations where third-party recruiters influence test ordering
Already a member? Log in here
